Pharmacologic efficacy in neuropsychiatry

A review of placebo-controlled treatment trials. A report of the ANPA Committee on Research

Teresa A. Rummans, Edward C. Lauterbach, C. Edward Coffey, Donald R. Royall, Jeffrey L. Cummings, Stephen Salloway, James Duffy, Daniel Kaufer

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Psychiatric disorders frequently compound the disability and complicate the management of neurologic conditions. These disorders result in increased morbidity for the person afflicted, stress for the caregiver, and financial burden. This study reviews the randomized double-blind placebo-controlled pharmacologic treatment trials of psychosis, depression, anxiety, and agitation in neurologic conditions form 1966 to 1998. Ten studies involving psychosis, 13 involving depression, and 20 involving anxiety-agitation meeting the committee's criteria were identified. Relatively few randomized double-blind placebo-controlled pharmacologic treatment trials of psychiatric disorders complicating neurologic disease have been conducted. These trials do not strongly support one specific pharmacologic approach to treatment. Further study of newer psychotropic agents, augmentation strategies, and novel use of other agents may help improve the treatment of psychiatric disorders observed in patients with neurologic disease.

Original languageEnglish (US)
Pages (from-to)176-189
Number of pages14
JournalJournal of Neuropsychiatry and Clinical Neurosciences
Volume11
Issue number2
StatePublished - Mar 1999

Fingerprint

Neuropsychiatry
Placebos
Psychiatry
Nervous System Diseases
Research
Psychotic Disorders
Nervous System
Anxiety
Depression
Therapeutics
Caregivers
Morbidity

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)

Cite this

Rummans, T. A., Lauterbach, E. C., Coffey, C. E., Royall, D. R., Cummings, J. L., Salloway, S., ... Kaufer, D. (1999). Pharmacologic efficacy in neuropsychiatry: A review of placebo-controlled treatment trials. A report of the ANPA Committee on Research. Journal of Neuropsychiatry and Clinical Neurosciences, 11(2), 176-189.

Pharmacologic efficacy in neuropsychiatry : A review of placebo-controlled treatment trials. A report of the ANPA Committee on Research. / Rummans, Teresa A.; Lauterbach, Edward C.; Coffey, C. Edward; Royall, Donald R.; Cummings, Jeffrey L.; Salloway, Stephen; Duffy, James; Kaufer, Daniel.

In: Journal of Neuropsychiatry and Clinical Neurosciences, Vol. 11, No. 2, 03.1999, p. 176-189.

Research output: Contribution to journalArticle

Rummans, TA, Lauterbach, EC, Coffey, CE, Royall, DR, Cummings, JL, Salloway, S, Duffy, J & Kaufer, D 1999, 'Pharmacologic efficacy in neuropsychiatry: A review of placebo-controlled treatment trials. A report of the ANPA Committee on Research', Journal of Neuropsychiatry and Clinical Neurosciences, vol. 11, no. 2, pp. 176-189.
Rummans, Teresa A. ; Lauterbach, Edward C. ; Coffey, C. Edward ; Royall, Donald R. ; Cummings, Jeffrey L. ; Salloway, Stephen ; Duffy, James ; Kaufer, Daniel. / Pharmacologic efficacy in neuropsychiatry : A review of placebo-controlled treatment trials. A report of the ANPA Committee on Research. In: Journal of Neuropsychiatry and Clinical Neurosciences. 1999 ; Vol. 11, No. 2. pp. 176-189.
@article{3402f69a39c34613ad59c8b22b6c2e41,
title = "Pharmacologic efficacy in neuropsychiatry: A review of placebo-controlled treatment trials. A report of the ANPA Committee on Research",
abstract = "Psychiatric disorders frequently compound the disability and complicate the management of neurologic conditions. These disorders result in increased morbidity for the person afflicted, stress for the caregiver, and financial burden. This study reviews the randomized double-blind placebo-controlled pharmacologic treatment trials of psychosis, depression, anxiety, and agitation in neurologic conditions form 1966 to 1998. Ten studies involving psychosis, 13 involving depression, and 20 involving anxiety-agitation meeting the committee's criteria were identified. Relatively few randomized double-blind placebo-controlled pharmacologic treatment trials of psychiatric disorders complicating neurologic disease have been conducted. These trials do not strongly support one specific pharmacologic approach to treatment. Further study of newer psychotropic agents, augmentation strategies, and novel use of other agents may help improve the treatment of psychiatric disorders observed in patients with neurologic disease.",
author = "Rummans, {Teresa A.} and Lauterbach, {Edward C.} and Coffey, {C. Edward} and Royall, {Donald R.} and Cummings, {Jeffrey L.} and Stephen Salloway and James Duffy and Daniel Kaufer",
year = "1999",
month = "3",
language = "English (US)",
volume = "11",
pages = "176--189",
journal = "Journal of Neuropsychiatry and Clinical Neurosciences",
issn = "0895-0172",
publisher = "American Psychiatric Publishing Inc.",
number = "2",

}

TY - JOUR

T1 - Pharmacologic efficacy in neuropsychiatry

T2 - A review of placebo-controlled treatment trials. A report of the ANPA Committee on Research

AU - Rummans, Teresa A.

AU - Lauterbach, Edward C.

AU - Coffey, C. Edward

AU - Royall, Donald R.

AU - Cummings, Jeffrey L.

AU - Salloway, Stephen

AU - Duffy, James

AU - Kaufer, Daniel

PY - 1999/3

Y1 - 1999/3

N2 - Psychiatric disorders frequently compound the disability and complicate the management of neurologic conditions. These disorders result in increased morbidity for the person afflicted, stress for the caregiver, and financial burden. This study reviews the randomized double-blind placebo-controlled pharmacologic treatment trials of psychosis, depression, anxiety, and agitation in neurologic conditions form 1966 to 1998. Ten studies involving psychosis, 13 involving depression, and 20 involving anxiety-agitation meeting the committee's criteria were identified. Relatively few randomized double-blind placebo-controlled pharmacologic treatment trials of psychiatric disorders complicating neurologic disease have been conducted. These trials do not strongly support one specific pharmacologic approach to treatment. Further study of newer psychotropic agents, augmentation strategies, and novel use of other agents may help improve the treatment of psychiatric disorders observed in patients with neurologic disease.

AB - Psychiatric disorders frequently compound the disability and complicate the management of neurologic conditions. These disorders result in increased morbidity for the person afflicted, stress for the caregiver, and financial burden. This study reviews the randomized double-blind placebo-controlled pharmacologic treatment trials of psychosis, depression, anxiety, and agitation in neurologic conditions form 1966 to 1998. Ten studies involving psychosis, 13 involving depression, and 20 involving anxiety-agitation meeting the committee's criteria were identified. Relatively few randomized double-blind placebo-controlled pharmacologic treatment trials of psychiatric disorders complicating neurologic disease have been conducted. These trials do not strongly support one specific pharmacologic approach to treatment. Further study of newer psychotropic agents, augmentation strategies, and novel use of other agents may help improve the treatment of psychiatric disorders observed in patients with neurologic disease.

UR - http://www.scopus.com/inward/record.url?scp=0032958927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032958927&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 176

EP - 189

JO - Journal of Neuropsychiatry and Clinical Neurosciences

JF - Journal of Neuropsychiatry and Clinical Neurosciences

SN - 0895-0172

IS - 2

ER -